Details of the Drug
General Information of Drug (ID: DMTUHWM)
Drug Name |
Esreboxetine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
(S,S)-reboxetine; 98819-76-2; UNII-L8S50ZY490; PNU-165442G; L8S50ZY490; Norebox; Davedax; Solvex; (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; (2S)-2-[(S)-2-ethoxyphenoxy(phenyl)methyl]morpholine; (2S)-2-[(S)-(2-ethoxyphenoxy)-phenyl-methyl]morpholine; Prolift; Esreboxetine [USAN:INN]; Esreboxetine (USAN/INN); (S,S)-( )-Reboxetine; S-Reboxetine; PNU 165442g; 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate; Tocris-1982; NCGC00025335-01; SCHEMBL34534; Reboxetine mesylate; (+-)-(2R*)-2-((alphaR*)-alpha-(o-Ethoxyphenoxy)benzyl)morpholine; (S,S)-Reboxetine
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 313.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 6 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Fibromyalgia | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | MG30.01 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||